Cargando…
A 20-gene mutation signature predicts the efficacy of immune checkpoint inhibitor therapy in advanced non-small cell lung cancer patients
BACKGROUND: There is an unmet need to identify novel predictive biomarkers that enable more accurate identification of individuals who can benefit from immune checkpoint inhibitor (ICI) therapy. The US FDA recently approved tumor mutational burden (TMB) score of ≥ 10 mut/Mb as a threshold for pembro...
Autores principales: | Hu, Xilin, Guo, Jing, Shi, Jianguang, Li, Da, Li, Xinjian, Zhao, Weijun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288780/ https://www.ncbi.nlm.nih.gov/pubmed/37349743 http://dx.doi.org/10.1186/s12890-023-02512-6 |
Ejemplares similares
-
The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors
por: Hu, Xilin, et al.
Publicado: (2021) -
Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations
por: Wang, Haowei, et al.
Publicado: (2023) -
Immune signature-based risk stratification and prediction of immune checkpoint inhibitor’s efficacy for lung adenocarcinoma
por: Yi, Ming, et al.
Publicado: (2021) -
Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations
por: Shang, Xiaoling, et al.
Publicado: (2023) -
Advances in immune checkpoint inhibitors therapy for small cell lung cancer
por: Li, Longhui, et al.
Publicado: (2023)